3 Hot Picks For February: AstraZeneca plc, BG Group plc, Rolls-Royce Holding PLC?

Will results from AstraZeneca plc (LON: AZN), BG Group plc (LON: BG) and Rolls-Royce Holding PLC (LON: BG) turn up bargains?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

What a dreadful January it’s been! With oil plunging below $30 a barrel at one point, and economic news from China getting worse, the FTSE 100 dipped as low as 5,640 points on 20 January — a massive 9.6% down on its end-of-2015 closing price!

Still, things are recovering cautiously, and with about half a day of January still to go the top index is back up to 5,980 points. And when markets are depressed, that means bargains, right?

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Pharma recovery

Look at AstraZeneca (LSE: AZN), whose shares have lost 9% over the past 12 months, to 4,382p. How does the price of oil and Chinese economic woes affect AstraZeneca’s long-term pharmaceuticals business? Not at all!

AstraZeneca has been in the process of focusing on its core businesses and beefing up its drugs development pipeline ever since new boss Pascal Soriot took the helm in October 2012, and we’re not expecting a return to earnings growth until 2017 at the earliest. On 4 February, we should have full-year results, providing the latest news on the firm’s rejuvenation strategy.

Things looked very stable at third-quarter time, and we’ve also seen quite a number of promising milestones in drug development along the way — Q3 R&D costs were up 18%, “reflecting the recent start of key Oncology trials“.

Meanwhile, AstraZeneca is still nicely profitable, on a P/E of 15.5 and offering a likely 4.2% dividend yield.

Takeover boost

We should have full-year results from BG Group (LSE: BG) on 5 February, but they’ll take a back seat to the ongoing takeover from Royal Dutch Shell. Originally revealed back in April 2015 before the oil price slide had really set in, the plan was put to the vote this week and both sets of shareholders have voiced their approval — Shell on Wednesday and BG on Thursday.

BG’s share price fell back from its initial boost as falling oil raised fears that Shell was overpaying and that the merger would be called off or the terms changed, but we’ve seen a 16% recovery to 1,040p, which is largely in line with the Shell offer.

Mergers and acquisitions were always a big possibility after the oil price set asset values tumbling, and in this case I think BG shareholders are enjoying the better deal.

Engineering boost

Rolls-Royce Holdings (LSE: RR) has been through tough times, with its shares losing half their value since last April’s peak, to 540p. The cause was a series of profit warnings due to very tough trading conditions, and the company is firmly in turnaround mode right now.

Full-year results are due on 12 February, after a third-quarter update warned that “Further market headwinds increase uncertainty for 2016“. At the time, outlook for the full year was adjusted to the lower end of previous guidance, though I think that might still turn out to be optimistic.

If results are better than expected, we could see an uptick in the share price, but with EPS already forecast to drop by 43% in 2016 to put the shares on a forward P/E of 18, I wouldn’t be buying now.

More on Investing Articles

Portrait of construction engineers working on building site together
Investing Articles

Is this FTSE 100 stock the best housebuilder to invest in?

One FTSE 100 housebuilding stock has outperformed all of its industry peers by a big margin this year. Should I…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

2 cheap dividend growth stocks I’d buy as the economy sinks

I'm searching for the best bargains to buy following recent market volatility. Here are two top dividend growth stocks I…

Read more »

estate agent welcoming a couple to house viewing
Investing Articles

Here’s 1 FTSE stock primed to benefit from the current housing market!

With the current housing market as it is, Jabran Khan explores a related FTSE stock that could provide stable and…

Read more »

Portrait of construction engineers working on building site together
Investing Articles

Here’s why this AIM-listed stock could be one of the best shares to buy!

This Fool is looking for the best shares to buy. Despite macroeconomic issues, this stock could be a great long-term…

Read more »

Elderly father and adult son work in the garden
Investing Articles

This penny stock could be set to soar! Should I buy shares?

This Fool looks closely at a penny stock operating in an exciting growth market that could see its shares rise…

Read more »

Illustration of bull and bear
Investing Articles

The next stock market recovery looks imminent

As the stock market bear gives way to the bull, some stocks are already turning up and I'm ready to…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

2 dividend shares to protect me from soaring inflation

Dividend shares can be an excellent way to keep up with inflation. Our writer explores several options to protect his…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is it time to buy Unilever stock?

Unilever stock has underperformed in the last five years. But with its portfolio of powerful brands, should I buy now…

Read more »